Leerink analyst Seamus Fernandez says that despite the narrowly positive FDA panel vote in favor of granting Eli Lilly's Jardiance an indication for reducing the incidence of cardiovascular death in diabetes patients with established CV disease, senior FDA officials appear convinced by the EMPA-REG results. The analyst sees this as a positive outcome for the company and its partner Boehringer Ingelheim, and adds that he believes an indication is likely. Fernandez recommends investors to buy Eli Lilly's stock at current levels and reiterates an Outperform rating and $101 price target on the shares.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here